It is not omega-3. The number just says where the first bend sits in a sixteen-carbon fat; it says nothing about what the fat does. Omega-7 (palmitoleic acid) acts through a narrow set of receptors and appears to behave less like fuel than like a signal, carrying a "calm inflammation, handle sugar better" message between tissues 1. The supplement comes from purified fish oil (sold as Provinal) or from sea buckthorn berry pulp.
The whole human case rests on one small trial. Sixty adults with high cholesterol, 220 mg a day of purified palmitoleate for a month, versus placebo: the inflammation marker hsCRP fell about 44%, LDL about 8%, triglycerides about 15%, and HDL rose about 5% 2. Coherent across the panel, modest, and never independently replicated — the trial was funded by the company that sells the ingredient. A twelve-week Japanese study saw the same directions, smaller 3.
The other real signal is dry eye: sea buckthorn oil over three months eased tear-film stress and symptoms 4. Where omega-7 sits in a surface oil layer — the tear film, the skin barrier — small benefits show up 5.
Who has an actual reason. Borderline cholesterol with a raised CRP, matching the trial. Evaporative dry eye, especially after menopause. Stubborn atopic dry skin, as an add-on to emollients. Everyone else — hoping for energy, focus, or weight loss — is buying a claim with no human evidence behind it.
About $20–35 a month, one capsule, no cycling. Easy to add; the catch is whether the label is honest about what's inside.
The fine print — when to skip it, and what people get wrong
Skepticism, three things. The "60% lower diabetes" figure is about trans-palmitoleate as a dairy biomarker, a different molecule and a correlation, not the capsule 6. Sea buckthorn seed oil has almost no omega-7; only pulp oil does. And omega-7 is not a weaker omega-3 — different receptors, evidence base dozens of trials larger over there 7.
How it fails. A cheap capsule delivering 30 mg instead of 200 won't reproduce the trial. Seed oil instead of pulp means you bought an omega-6 mix. Expecting fish-oil-scale effects from one sixty-person study. Skipping the follow-up labs, so you never learn if you responded.
When to check first. Fish-derived palmitoleate may thin the blood mildly at higher doses; ask your clinician if you're on warfarin, a DOAC, or headed to surgery. Pregnant or breastfeeding: excluded from the trials, so the safety data is absent, not reassuring.
- 1Cao H, Gerhold K, Mayers JR, Wiest MM, Watkins SM, Hotamisligil GS (2008). Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell. link
- 2Bernstein AM, Roizen MF, Martinez L (2014). Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: a double-blinded, randomized, placebo controlled study. Journal of Clinical Lipidology. link
- 3Yagi K, Inoue H, Hagihara Y, Ito S, Kawai S, Okamura S (2017). Effect of palmitoleic acid on insulin sensitivity and lipid profile in humans. Diabetology International. link
- 4Larmo PS, Järvinen RL, Setälä NL, Yang B, Viitanen MH, Engblom JR, Tahvonen RL, Kallio HP (2010). Oral sea buckthorn oil attenuates tear film osmolarity and symptoms in individuals with dry eye. Journal of Nutrition. link
- 5Yang B, Kalimo KO, Mattila LM, Kallio SE, Katajisto JK, Peltola OJ, Kallio HP (1999). Effects of dietary supplementation with sea buckthorn (Hippophaë rhamnoides) seed and pulp oils on atopic dermatitis. Journal of Nutritional Biochemistry. link
- 6Mozaffarian D, Cao H, King IB, Lemaitre RN, Song X, Siscovick DS, Hotamisligil GS (2010). Trans-palmitoleic acid, metabolic risk factors, and new-onset diabetes in U.S. adults: a cohort study. Annals of Internal Medicine. link
- 7Frigolet ME, Gutiérrez-Aguilar R (2017). The role of the novel lipokine palmitoleic acid in health and disease. Advances in Nutrition. link
Omega-7 (Palmitoleic Acid)
One soft-gel capsule daily with food. No protocol, no preparation, no behaviour change beyond remembering it — trivially low effort once the habit is set.
Purified palmitoleate (Provinal-based products) runs ~$20–35/month at the studied dose, sea buckthorn oil ~$15–25/month. Yearly cost ~$200–420 — minor but real, in the $50–$500/year band.
Bernstein 2014 RCT showed hs-CRP reduced ~44%, LDL −8%, TG −15%, HDL +5% at 220 mg/day over 30 days; Larmo 2010 RCT showed objective dry-eye improvement at 3 months on sea buckthorn oil; Yagi 2017 reproduced metabolic improvements in 12 weeks. Real but small day-to-day improvement for responder subgroups.
One ~60-person single-centre industry-sponsored RCT (Bernstein 2014) plus one smaller Japanese trial (Yagi 2017) for the metabolic claims; one moderate dry-eye RCT (Larmo 2010); mechanism is well-mapped from mouse work (Cao 2008). No independent multi-site replication, no large outcome trial. Sparse and preliminary but not absent.
Sea buckthorn oil and purified palmitoleate are structural components of meibomian-gland and sebaceous-gland lipids; small trials show modest improvement in dry-eye signs and dry skin (Larmo 2010; Yang 1999). The visible cosmetic effect within days is minor — not the reason to recommend it.
Long-term mucous-membrane and skin lipid support is plausible from the mechanism (PPAR-α activation, barrier-lipid supplementation) and consistent with the modest atopic-dermatitis improvement (Yang 1999) and post-menopausal vaginal-atrophy improvement (Larmo 2014). Contribution is real but small relative to the appearance trajectory.
Lipid and hs-CRP improvements (Bernstein 2014) are directionally relevant to cardiovascular mortality, but the effect sizes are smaller than statins or icosapent ethyl, no hard-outcome trials exist, and the much-cited trans-palmitoleate diabetes-incidence data (Mozaffarian 2010, 2013) is for a different isomer and doesn't transfer to supplements. Marginal contribution at best.